2025-04-19 - Analysis Report
## Teva Pharmaceutical Industries Ltd ADR (TEVA) Stock Review

**0. Key Figures & Initial Analysis:**

TEVA's cumulative return of 31.57% significantly underperforms the S&P 500's (VOO) 76.18% return over the same period, resulting in a large negative divergence.  The company's recent price action shows it is trading below its 5, 20, and 60-day moving averages, suggesting a bearish trend.  Negative PPO and low RSI values also point towards a bearish sentiment. Further analysis is needed to determine the investment viability.


**1. Performance Comparison with S&P 500:**

Teva Pharmaceutical Industries Ltd ADR is a global pharmaceutical company.  The provided data shows TEVA underperformed the S&P 500 (VOO) by 44.6 percentage points. This places TEVA at the 56.9th percentile of its historical performance relative to the S&P 500 based on the provided min/max range. The alpha values consistently show underperformance against the market benchmark. The beta values fluctuate and suggest varying levels of market sensitivity.


**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta   | Cap(B) |
|------------|--------|--------|--------|--------|--------|
| 2015-2017  | -43.0% | 58.5%  | -75.0% | 0.1    | 21.7   |
| 2016-2018  | -41.0% | 70.4%  | -62.0% | -0.0   | 17.7   |
| 2017-2019  | -17.0% | 70.4%  | -53.0% | -0.3   | 11.2   |
| 2018-2020  | -1.0%  | 70.4%  | -31.0% | -0.2   | 11.1   |
| 2019-2021  | -23.0% | 58.4%  | -83.0% | -0.2   | 9.2    |
| 2020-2022  | 26.0%  | 74.8%  | 18.0%  | -0.3   | 10.5   |
| 2021-2023  | 38.0%  | 74.8%  | 18.0%  | -1.0   | 12.0   |
| 2022-2024  | 123.0% | 74.8%  | 102.0% | -0.9   | 25.3   |
| 2023-2025  | 41.0%  | 76.0%  | 27.0%  | -0.2   | 15.7   |

**Note:** There's a discrepancy between the provided Alpha and MDD values in several rows.  The data needs clarification.  The negative alpha consistently indicates underperformance relative to the market.


**2. Recent Price Movement:**

* **Closing Price:** $13.65
* **5-Day Moving Average:** $13.55
* **20-Day Moving Average:** $14.55
* **60-Day Moving Average:** $16.25

The closing price is below all three moving averages, reinforcing the bearish trend.  The recent 1.64% increase suggests a potential short-term bounce, but the overall trend remains negative.


**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.42 (Medium Risk)
* **RSI:** 36.83 (Suggests oversold conditions, but not a strong buy signal on its own)
* **PPO:** -0.31 (Negative PPO indicates bearish momentum)
* **20-Day Relative Divergence Change:** +6.1 (Short-term upward movement)
* **Expected Return (2+ years):** -57.6% (Significant underperformance compared to S&P 500 is projected).  This extremely negative expected return warrants serious consideration.

The recent price change of 1.64% suggests a minor bounce, but the overall indicators paint a bearish picture.  The negative expected return raises serious concerns about long-term investment.


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue      |
|------------|--------|--------------|
| 2024-11-06 | -$0.39 | $4.33B       |
| 2024-07-31 | -$0.75 | $4.16B       |
| 2024-05-08 | -$0.12 | $3.82B       |
| 2023-11-09 | $0.07  | $3.85B       |
| 2024-02-12 | $0.06  | $3.85B       |

Recent earnings show fluctuating EPS, with several quarters reporting losses.  Revenue remains relatively stable, but the negative EPS is a major concern.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter     | Revenue | Profit Margin |
|-------------|---------|---------------|
| 2024-12-31 | $4.23B  | 50.15%        |
| 2024-09-30 | $4.33B  | 49.60%        |
| 2024-06-30 | $4.16B  | 48.61%        |
| 2024-03-31 | $3.82B  | 46.37%        |
| 2023-12-31 | $4.46B  | 54.18%        |

**Capital and Profitability:**

| Quarter     | Equity  | ROE     |
|-------------|---------|---------|
| 2024-12-31 | $5.37B  | -4.04%  |
| 2024-09-30 | $6.07B  | -7.21%  |
| 2024-06-30 | $6.36B  | -13.30% |
| 2024-03-31 | $7.28B  | -1.91%  |
| 2023-12-31 | $7.51B  | 5.72%   |

Profit margins are relatively healthy, but the negative ROE in recent quarters indicates concerns about profitability relative to shareholder equity.


**6. Overall Analysis:**

TEVA significantly underperforms the S&P 500, showing negative alpha and beta values.  Recent price action, technical indicators (RSI, PPO), and a projected negative long-term return suggest a bearish outlook. While revenue remains relatively stable, negative EPS and ROE raise significant concerns.  The data strongly suggests TEVA is a high-risk investment at this time.  Further in-depth research into the company's specific challenges and future prospects is strongly recommended before considering any investment.  The discrepancies in the provided Alpha and MDD data necessitate further verification of the data's accuracy and source.
